||Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 501 active entries
6100, avenue Royalmount
Montreal, QC, H4P 2R2
Replicor is developing a new drug that will revolutionize the
treatment of patients with chronic hepatitis B which
affects up to 350 million patients worldwide. By blocking the release of a
viral protein called HBsAg, our drug allows the re-establishment of a
proper immune response to the infection and results in a high proportion of
patients achieving long term immunological control over their infection.
The efficacy and safety of our drug has already been successfully
demonstrated in a randomized phase II human clinical trial. Based on
Replicor's current clinical trial results, it is projected that a functional
control rate of 80% will be achieved when our drug is used in combination
with currently available approved drugs. The most effective treatment to
date can only achieve a rate of functional control less than 10 %.
Co-infection with hepatitis B and hepatitis D affects 15-20 million patients
worldwide and is the most aggressive form of viral hepatitis leading to a
high rate of cirrhosis. No drug has been approved for this condition making
this an orphan drug indication with the possibility of accelerated approval
by the FDA and EMA. We have demonstrated in a recent proof of concept
clinical trial published in The Lancet Gastroenterology & Hepatology, that
7 patients out of 11 have completely eliminated the HDV virus from their
blood when receiving our drug in combination with Pegasys making our
drug the most promising asset in this field.
Longer treatment durations are expected to achieve higher rates of cure for this condition.
Last update of this entry: March 03, 2020